SCHEMBL423526

SCHEMBL423526

OC[C@H]1OC=C[C@@H](O)[C@H]1O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 3/20 0.33
TSHR P16473 2/20 0.33
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
LGALS8 O00214 4/20 0.32
LGALS1 P09382 2/20 0.32
LGALS3 P17931 2/20 0.32
LGALS9 O00182 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GBA1 P04062 1/20 0.31
CA12 O43570 2/20 0.31
CA9 Q16790 2/20 0.31
CA2 P00918 1/20 0.31
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13822005 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL154476 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL6534721 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL10045765 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL12205165 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL7948561 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL12921945 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL20844917 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL22472219 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA
SCHEMBL31384230 1.00 FUCA1 (0.52) FUCA1L3MBTL1ALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122091405-A Composite activated carbon and preparation method and application thereof 2026-05-26 CN claimed
US-20230192748-A1 Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug DOUBLERAINBOW BIOSCIENCES INC. 2023-06-22 US claimed
US-20230193336-A1 ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION DOUBLERAINBOW BIOSCIENCES INC. 2023-06-22 US claimed
EP-4196516-A1 POLYMERISATION PROCESSES The University Of Bath (GB) 2023-06-21 EP claimed
US-20230124589-A1 Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis DOUBLERAINBOW BIOSCIENCES INC. 2023-04-20 US claimed
EP-4121546-A1 ETOPOSIDE GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF AS AN ANTI-CANCER DRUG Doublerainbow Biosciences Inc. (US) 2023-01-25 EP claimed
CN-115279915-A Etoposide glycoside, preparation method thereof and application thereof as anticancer drug 德瑞生物医药股份有限公司 2022-11-01 CN claimed
WO-2022034321-A1 POLYMERISATION PROCESSES THE UNIVERSITY OF BATH (GB) 2022-02-17 WO claimed
WO-2021188457-A1 ETOPOSIDE GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF AS AN ANTI-CANCER DRUG DOUBLERAINBOW BIOSCIENCES INC. (US) 2021-09-23 WO claimed
WO-2021188459-A1 IVACAFTOR GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF IN TREATING CYSTIC FIBROSIS DOUBLERAINBOW BIOSCIENCES INC. (US) 2021-09-23 WO claimed
JP-H08500012-A 1996-01-09 JP claimed
EP-0654087-A1 A FACILE ENZYMATIC SYNTHESIS OF GALACTOSYL-BETA-1,3 GLYCALS THE SCRIPPS RESEARCH INSTITUTE (US) 1995-05-24 EP claimed
EP-0448412-B1 A route to glycals in the allal and gulal series UNIV YALE (US) 1995-02-15 EP claimed
EP-0598051-A1 ENZYMATIC METHOD FOR SYNTHESIS OF CARBOHYDRATES BIOFLEXIN AB (SE) 1994-05-25 EP claimed
WO-1994002624-A1 A FACILE ENZYMATIC SYNTHESIS OF GALACTOSYL-BETA-1,3 GLYCALS THE SCRIPPS RESEARCH INSTITUTE (US) 1994-02-03 WO claimed
US-5278301-A Route to glycals in the allal and gulal series YALE UNIVERSITY (US) 1994-01-11 US claimed
WO-1993003168-A1 ENZYMATIC METHOD FOR SYNTHESIS OF CARBOHYDRATES NILSSON KURT (SE) 1993-02-18 WO claimed
EP-0448412-A2 A route to glycals in the allal and gulal series YALE UNIVERSITY (US) 1991-09-25 EP claimed
US-4935503-A One step; using peroxydisulfate, ferrous, azide, and chloride salt BIOMIRA, INC. (CA) 1990-06-19 US claimed
EP-0340780-A2 Azidochlorination and diazidization of glycals BIOMIRA, INC. (CA) 1989-11-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124589-A1 Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis UGGT1, UGDH, GALE FUCA1 7/4885L3MBTL1 1359/4885ALDH1A1 395/4885
US-20230193336-A1 ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION UGDH, IDH1, G6PD FUCA1 31/4885L3MBTL1 1574/4885ALDH1A1 292/4885
US-20230192748-A1 Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug GALE, UGGT1, DERA FUCA1 8/4885L3MBTL1 1063/4885ALDH1A1 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.